Track topics on Twitter Track topics that are important to you
Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se
Physostigmine Salicylate Injection
Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formul...
We have published hundreds of Calabar AB news stories on BioPortfolio along with dozens of Calabar AB Clinical Trials and PubMed Articles about Calabar AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Calabar AB Companies in our database. You can also find out about relevant Calabar AB Drugs and Medications on this site too.